News
FDA clears Seagen, Genmab's Tivdak ADC for cervical cancer
Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or meta
